The Education SBIR Track Almost No One Talks About: ED/IES Released FY2026 Phase IA, Phase IB, and Direct-to-Phase-II With June 29 Deadlines, \$250K Feasibility Awards, and \$1M Commercialization Awards — Here Is the Edtech Funding Lane Most Founders Miss.

The federal SBIR portfolio is dominated, in public attention and venture conversation, by the defense and health agencies. Department of War SBIR is a $2-billion-plus annual program with a continuous topic release cadence and a clear path to large procurement awards. NIH SBIR runs at roughly $1.2 billion annually with a well-understood path from Phase I to Phase II to commercialization. NSF SBIR just restarted with a $250 million FY26 allocation and a Strategic Breakthrough escalator that tops out at $30 million per company.

Below those headline programs, the Department of Education's Institute of Education Sciences runs a structurally different SBIR program that almost no founders outside the education-technology sector consider. ED/IES SBIR released its FY2026 Phase IA, Phase IB, and Direct-to-Phase-II solicitations on April 30, 2026, with proposal deadlines on June 29 at 11AM EDT (for Phase IA and IB) and 2PM EDT (for Direct-to-Phase-II). Phase IA and Phase IB awards are $250,000 for nine months. Direct-to-Phase-II awards are $1,000,000 for two years. The application window is narrow — fewer than two months from solicitation release to proposal due date — and the question deadline already closed on May 21.

For founders building education technology, education-data infrastructure, special-education tools, or commercial products that sit on top of university-developed evidence-based education innovations, the ED/IES SBIR program is one of the cleanest non-dilutive funding paths in the federal portfolio. For founders outside that sector who do not realize the program exists, this piece is an introduction to a category most miss.

Why the ED/IES SBIR Program Is Structurally Different

Three structural features distinguish ED/IES SBIR from the larger SBIR programs at DoD, NIH, and NSF. Understanding the differences matters because each one changes what a strong proposal looks like and which companies should consider applying.

The first structural difference is the explicit separation of Phase IA (novel technologies) and Phase IB (new components for existing products). Most SBIR programs collapse the two into a single Phase I track, leaving applicants to figure out for themselves whether their work fits the feasibility framing. ED/IES treats them as distinct funding lanes with distinct evaluation criteria. Phase IA requires that projects be "independent from (will not be integrated with) any other existing education technology prototypes or products" and that they employ "different technological approaches than prior work." Phase IB, by contrast, requires that the new component be "distinct from the existing education technology prototype or product" and use "different development methods." A company applying for the wrong phase will be screened against during administrative review, regardless of how strong the underlying technical work is.

The second structural difference is the Direct-to-Phase-II eligibility constraint. Direct-to-Phase-II under ED/IES is explicitly restricted to "scaling evidence-based innovations originally developed by universities or non-profit research organizations." This is one of the cleanest IP-licensing-to-commercialization pathways in the federal SBIR portfolio. A founder who has licensed an evidence-based education innovation from a university research lab, who has commercial-product ambitions, and who can credibly argue that the underlying work is "evidence-based" within IES's framework can skip the Phase I feasibility step entirely and apply directly for $1,000,000 over two years. The constraint is real — IES is explicit that "projects that focus on advancing innovations that are not evidence-based are not eligible" — but for companies whose business model is built on commercializing university research, the constraint is actually an enabling feature rather than a barrier.

The third structural difference is the duplicate-proposal restriction. ED/IES SBIR explicitly prohibits companies from "submitting identical or similar proposals across multiple 2026 solicitations," with duplicates rejected at administrative review. Companies that submit one proposal to Phase IA and a similar proposal to Phase IB will see both rejected. Companies that want to pursue multiple awards in the FY2026 cycle need to submit "multiple distinct proposals with different goals" — which is allowed and not uncommon, but which requires careful upfront planning about which distinct technical questions to pursue.

The Award Structures: $250K Phase I, $1M Direct-to-Phase-II

The Phase IA and Phase IB awards are $250,000 for nine months. Nine months is short relative to the twelve-to-eighteen-month windows common at other SBIR agencies, and the implication for proposal scoping is that the planned work needs to fit credibly within a nine-month execution timeline. Companies that have built their internal product roadmaps around twelve-month-or-longer development cycles need to scope the Phase I work tightly: a single focused technical demonstration, a single validation study, and a clear hand-off point at the end of month nine that sets up the company for a Phase II application or a commercial release.

The $250,000 award size is also smaller than the $305,000 NSF SBIR Phase I cap and the variable-size NIH SBIR Phase I awards (which can run higher in some institutes). The smaller size argues for tighter scoping and for companies that have already done substantial founder-funded or grant-funded preliminary work. ED/IES is not the right Phase I program for a company that needs the SBIR award to be its primary capital — the budget envelope is too narrow. It is the right program for a company that has built foundational work outside the SBIR program and needs $250,000 to take a specific edtech innovation from prototype to validated feasibility.

The Direct-to-Phase-II awards are $1,000,000 for two years. The award size is comparable to NSF SBIR Phase II at $1,250,000 and below the larger NIH Phase II envelopes, but the Direct-to-Phase-II path is the structural advantage. Companies that are eligible — those scaling evidence-based innovations originally developed by universities or non-profit research organizations — can skip the Phase I derisking gate entirely and apply directly for the commercialization-stage award. For university spinouts, licensed-research companies, and founders whose product is built on top of an evidence-based education research finding, the Direct-to-Phase-II path is a structurally underutilized funding lane.

Eligibility, Registration, and the Restrictions That Bite

ED/IES SBIR applicants must register on SAM.gov with a Unique Entity Identifier before submission. SAM.gov registration is the most common preventable cause of administrative rejection in federal SBIR programs — the registration process can take several weeks, and companies that wait until the submission window opens often find themselves locked out of the cycle. With the June 29 deadline and the late-April solicitation release, companies that have not started SAM.gov registration by the time they read this should treat that as the first action item.

The duplicate-proposal restriction is worth re-emphasizing. Companies pursuing multiple proposals in the FY2026 cycle need to ensure that each proposal is "distinct with different goals." The administrative review will look for substantive overlap in technical approach, intended user population, and commercial transition plan. The conservative practice for companies considering multiple proposals is to articulate the distinguishing technical question for each proposal up front and to write each proposal as though it were the only one being submitted.

The question deadline closed on May 21, 2026. Companies that did not submit clarifying questions during the question window are working with the solicitation as written. For most applicants, this is a manageable constraint — the FY2026 ED/IES solicitations are written in continuity with prior years and the structural requirements are well-documented. For companies with novel technical approaches that do not map cleanly to prior IES funding patterns, the lack of a current question window is a real disadvantage; the right move in that case is to consult prior years' question-and-answer documents on the IES website and to look for guidance that anticipates the current question.

Which Founders Should Actually Apply

ED/IES SBIR is not the right program for every edtech founder. Three filters narrow the population of strong applicants.

The first filter is mission fit. ED/IES funds work that contributes to U.S. education research and practice — special education tools, K-12 instructional technology, postsecondary student supports, education data infrastructure, and adult basic education tools all fit. Workforce-training products that target employer customers without an education-research framing do not fit cleanly. Health-adjacent tools that touch schools but are fundamentally health interventions belong in NIH SBIR, not ED/IES. Pure consumer education products without an evidence-based research framing do not fit. Founders whose work does not clearly contribute to U.S. education outcomes will be selected against in the merit review.

The second filter is evidence orientation. ED/IES values evidence-based product design, validation studies, and explicit references to the education research literature. Founders who can credibly cite the underlying research base for their product and who can articulate a validation plan that produces usable evidence will score better than founders pitching the same product without that framing. For Direct-to-Phase-II, evidence orientation is not optional — it is a hard eligibility requirement.

The third filter is execution timeline alignment. The nine-month Phase I window and the two-year Direct-to-Phase-II window favor companies that can credibly execute focused technical work within those windows. Companies whose product roadmaps require multi-year development cycles or whose validation studies require multi-year cohort tracking will struggle to scope ED/IES proposals credibly.

Founders who clear those three filters — mission fit, evidence orientation, and execution timeline alignment — have access to one of the most structurally underserved SBIR funding lanes in the federal portfolio. The competition is real but is smaller than at the headline SBIR programs, the path from Phase I to commercialization is more direct than at most agencies, and the Direct-to-Phase-II eligibility for university-licensed innovations is a structural advantage that most founders do not exploit.

Positioning for the June 29 Deadline

With less than three weeks to the deadline at the time of writing, the practical proposal preparation calculus is tight. SAM.gov registration should be in motion or completed. The decision between Phase IA, Phase IB, and Direct-to-Phase-II should be made early and consistently throughout the proposal narrative — proposals that read as though the authors were uncertain which phase they were applying for will be selected against. The technical narrative should fit the nine-month or twenty-four-month execution timeline credibly, with a specific work plan, specific milestones, and specific deliverables at each milestone.

The commercialization narrative should be written with IES's specific commercialization framework in mind. Unlike the more open-ended commercialization narratives that NSF SBIR accepts, ED/IES expects a commercialization plan that articulates how the product will reach U.S. schools, districts, postsecondary institutions, or adult-learning settings. Direct-to-customer consumer plays, while not categorically excluded, need to be framed in terms that connect back to U.S. education outcomes.

For evidence-based products eligible for Direct-to-Phase-II, the proposal should explicitly identify the underlying university or non-profit research that the product builds on, should articulate the licensing or partnership arrangement that links the company to that research, and should document the evidence base in the technical narrative. A Direct-to-Phase-II proposal that reads as a commercial pitch with a university affiliation appended will be selected against. A Direct-to-Phase-II proposal that reads as a credible commercialization of a specific evidence-based research finding, with clear authorial continuity between the original research and the commercial product, will be selected for.

ED/IES SBIR is not the program that will turn into a $30 million commitment over the company's lifetime the way NSF's new Strategic Breakthrough lane might (deep analysis here). It is also not the program that produces $50 million Phase III procurement contracts the way DoW SBIR can (deep analysis here). It is the program that, for the right founder, provides clean and underexploited non-dilutive capital in a sector that the headline SBIR agencies do not touch — and it is the program whose FY2026 windows close in less than three weeks.